Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.
Keynote by Michael Berman, Former President at Boston Scientific and Healthcare IT entrepreneur and innvestor, about US digital healthcare investment trends and opportunities for the mHealth Israel meetup community
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...Rafael Casiano
As clinical trial outsourcing to CROs continues to increase, competition among CROs is becoming fierce, and sponsors are under pressure to do more with less. To respond, experienced CROs understand they must exploit every opportunity to gain a competitive edge. And, while technology can be a key differentiator, simply being “data-driven” is not enough to win studies. CROs must find consistent and predictable methods to accelerate clinical trial recruitment.
The Clinical and Economic Impact of Value-Based Implants in Orthopaedic Traum...April Bright
Learn about the market forces driving value-based care in orthopaedics (ASCs, bundled payments), and the clinical outcomes and economic impacts imparted by the use of value-based implants.
Keynote by Michael Berman, Former President at Boston Scientific and Healthcare IT entrepreneur and innvestor, about US digital healthcare investment trends and opportunities for the mHealth Israel meetup community
New Disruptive Technology Helps CROs and Pharma Accelerate Oncology-Focused C...Rafael Casiano
As clinical trial outsourcing to CROs continues to increase, competition among CROs is becoming fierce, and sponsors are under pressure to do more with less. To respond, experienced CROs understand they must exploit every opportunity to gain a competitive edge. And, while technology can be a key differentiator, simply being “data-driven” is not enough to win studies. CROs must find consistent and predictable methods to accelerate clinical trial recruitment.
The Clinical and Economic Impact of Value-Based Implants in Orthopaedic Traum...April Bright
Learn about the market forces driving value-based care in orthopaedics (ASCs, bundled payments), and the clinical outcomes and economic impacts imparted by the use of value-based implants.
This is a Dean's Case Competition project in Som-Binghamton University. I did it with my team in Spring 2014 to present our the overall situation of Medtronic Inc.
Lies CMIOs Tell- Dr. David Allard, Henry Ford Health SystemLevi Shapiro
Presentation for mHealth Israel by Dr. David Allard, Chief Medical Information Officer, Henry Ford Health System. The lecture discusses why EMRs lag other innovations in Healthcare and other industries. David then proposes an approach to innovation and examines common issues with which CMIOs contend. He finishes with a few successful case studies.
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe JankowskiLevi Shapiro
Webinar presentation for the mHealth Israel community by Joe Jankowski, PhD, Director, Innovation, Henry Ford Innovation Institute at the Henry Ford Health System in Detroit, Michigan. This is a systematic review of the key barriers inhibiting adoption of new technologies across health systems, with an emphasis on specific challenges for startups. Key factors include existing workflows, noise in the system, procurement cycle, costs, IT issues, self interests, value proposition, validation plan, Payer inefficiencies. Suggestion is to partner early, align to a major current problem and to focus on the health system rather than your own product. Also, build out a diverse team of stakeholders, use retrospective data to conduct scenario analysis, set appropriate expectations for time and cost.
Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.
LEARN MORE ABOUT INVESTOR OPPORTUNITIES HERE: https://vivaquant.sppx.io/
We all know someone who has had a heart attack or other cardiac condition. And despite significant therapeutic and diagnostics advancements, heart disease and cardiac events remain the leading causes of death in both men and women in the United States and cost more than $200 billion in health care services annually. Earlier and more accurate arrhythmia diagnosis can help change that, but we need your help!
This is a Dean's Case Competition project in Som-Binghamton University. I did it with my team in Spring 2014 to present our the overall situation of Medtronic Inc.
Lies CMIOs Tell- Dr. David Allard, Henry Ford Health SystemLevi Shapiro
Presentation for mHealth Israel by Dr. David Allard, Chief Medical Information Officer, Henry Ford Health System. The lecture discusses why EMRs lag other innovations in Healthcare and other industries. David then proposes an approach to innovation and examines common issues with which CMIOs contend. He finishes with a few successful case studies.
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe JankowskiLevi Shapiro
Webinar presentation for the mHealth Israel community by Joe Jankowski, PhD, Director, Innovation, Henry Ford Innovation Institute at the Henry Ford Health System in Detroit, Michigan. This is a systematic review of the key barriers inhibiting adoption of new technologies across health systems, with an emphasis on specific challenges for startups. Key factors include existing workflows, noise in the system, procurement cycle, costs, IT issues, self interests, value proposition, validation plan, Payer inefficiencies. Suggestion is to partner early, align to a major current problem and to focus on the health system rather than your own product. Also, build out a diverse team of stakeholders, use retrospective data to conduct scenario analysis, set appropriate expectations for time and cost.
Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.
LEARN MORE ABOUT INVESTOR OPPORTUNITIES HERE: https://vivaquant.sppx.io/
We all know someone who has had a heart attack or other cardiac condition. And despite significant therapeutic and diagnostics advancements, heart disease and cardiac events remain the leading causes of death in both men and women in the United States and cost more than $200 billion in health care services annually. Earlier and more accurate arrhythmia diagnosis can help change that, but we need your help!
business model, business model canvas, mission model, mission model canvas, customer development, lean launchpad, lean startup, stanford, startup, steve blank, entrepreneurship, I-Corps, Stanford
The Pegwin Insights software platform is used by caregivers at the point of care to measure and monitor a patient’s risk profile and receive early insight into a patient’s deterioration so that timely intervention and preventive action can be taken to avoid post-operative complications. Pegwin Insights is the only evidence-based Machine Learning and AI solution to assist caregivers with better-than-human accuracy in real-time.
Chris Cleary, Vice President of Corporate Development, Medtronic presented at MEDTECH 2014 on Fulfilling the Mission: Medtronic Embraces Change to Respond to an Evolving Healthcare Landscape.
Cell & Gene Therapy post-approval solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
World’s first one wrist ecg band and other revolutionary products from Europe’s fastest growing biotech company in $142b market investment opportunity with 28x return in 3 years
"Empowering Consumer with Smart Devices and Smart Data for Proactive ‘Health ...Hyper Wellbeing
"Empowering Consumer with Smart Devices and Smart Data for Proactive ‘Health Care’" - Maryam Ziaei (Founder/CEO, iSono Health)
Delivered at the inaugural Hyper Wellbeing Summit, 14th November 2016, Mountain View, California.
For more information including details of subsequent events, please visit http://hyperwellbeing.com
The summit was created to foster a community around an emerging industry - Wellness as a Service (WaaS). Consumer technologies, in particular wearables and mobile, are powering a consumer revolution. A revolution to turn health and wellness into platform delivered services. A revolution enabling consumer data-driven disease risk reduction. A revolution extending health care past sick care towards consumer-led lifelong health, wellness and lifestyle optimization.
WaaS newsletter sign-up http://eepurl.com/b71fdr
@hyperwellbeing
Cell & Gene Therapy post-approval solutions to reduce scientific, regulatory and commercial risks, and accelerate development wherever you are in your product's development.
By: Fiona Fitzgerald, GE Healthcare Canada
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
Sona Nanotech is a nanotechnology life sciences firm that has developed multiple proprietary methods for the manufacture of various types of gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona Nanotech's gold nanotechnologies may be adapted for use in applications as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
Garibaldi Resources January 2021 PresentationChadLevesque1
Garibaldi Resources is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.
Granada Gold Mine continues to develop the Granada gold property, located near Rouyn-Noranda, Que. Approximately 120,000 metres of drilling have been completed to date on the property, focused mainly on the extended Long Bars zone, which trends two kilometres east-west over a potential 5.5 kilometres of mineralized structure. The highly prolific Cadillac break, the source of greater than 75 million ounces of gold production in the past century, cuts through the northern part of the Granada property, but is not necessarily indicative of mineralization hosted on the company's property.
The Granada shear zone and the South shear zone contain, based on historical detailed mapping as well as from current and historical drilling, up to 22 mineralized structures trending east-west over 5.5 kilometres. Three of these structures were mined historically from two shafts and two open pits. Historical underground grades include eight grams per tonne to 10 grams per tonne gold from two shafts down to 236 m and 498 m, with open-pit grades from five grams per tonne to 3.5 grams per tonne gold.
The company is in possession of all mining permits required to commence the initial mining phase, which will allow the company to mine up to 550 tonnes per day.
Garibaldi Corporate Presentation October 2020ChadLevesque1
Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.
Granada Gold Mine Inc. is continuing to develop the Granada Gold Property near Rouyn-Noranda, Quebec. The property includes the former Granada gold mine which produced more than 50,000 ounces of gold at 10 grams per tonne gold in the 1930's before a fire destroyed the surface buildings. Approximately 120,000 meters of drilling has been completed to date on the property, focused mainly on the extended LONG Bars zone which trends 2 kilometers east west over a potential 5.5 kilometers mineralized structure. The highly prolific Cadillac Trend, the source of 50 million plus ounces of gold production in the past century, cuts right through the north part of the Granada property on a line running from Val-d'Or to Rouyn-Noranda Quebec.
The Company is in possession of all permits required to commence the initial mining phase known as the "Rolling Start", which allows the company to mine up to 550 tonnes per day, capable of producing up to 675,000 tonnes of ore over a 3-year period of time.
Ridgestone Mining is a Canadian mineral exploration company focused on its wholly owned, high-grade Rebeico gold-copper project located in Sonora, Mexico.
Headquartered in Philadelphia, Vsblty is the world leader in pro-active digital display, which transforms retail and public spaces, as well as place-based media networks with software-as-a-service-based audience measurement and security software that uses artificial intelligence and machine learning.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
VentriPoint Diagnostic Ltd. Presentation
1. Ultrasound AI for Cardiac
Imaging
A Better Way to Analyze the Whole Heart
OTC: VPTDF & TSX-V: VPT
2. Symbol: TSX-V: VPT & OTC: VPTDF
Capital Structure
Shares Outstanding 127M
Shares Fully Diluted 148M
Recent share price CDN$.32
52-Week Range CDN$.07-.325
Market Cap ~CDN$40M
Insider ownership
(FD)
6%
Public Float
ownership
Debt
Cash
Liquidity
94%
None
2 years
CDN$600,000/day
TSXV:VPT
2
3. An AI imaging company with proprietary 4
quadrant cardiac analysis technology
Overview
US-FDA approved + EU, Canada and China
Entering high growth phase with goal to place
80-100 units by mid-2022
Clear path to liquidity providing attractive
shareholder ROI
Placed in first 11 clinical sites and 11 more
placements in process
TSXV:VPT
3
4. Market Need
Although the 2D echocardiogram is the most commonly-used
cardiac diagnostic tool world-wide, it does NOT:
obtain accurate and reliable volumes for any heart chamber
measure right ventricle (RV) volume & ejection fraction in children
provide a standard metric for all cardiac patients
work on difficult to scan (e.g. obese) patients
Prior to VMS+3.0, this degree of detail has required a referral for an MRI
scan, which is:
limited in it’s accessibility - an issue in most communities
significantly more costly than ultrasound
less efficient
requires contrast media and often sedation of patients
5. VMS+ 3.0™ vs MRI
Factor MRI VMS+ 3.0™
Scan time 60 – 120 minutes 5 minutes
Patient movement Motionless Full movement allowed
Patient preparation Sedation and injection of
contrast media
None
Image availability 1 – 2 days Immediately
Analysis Radiologist (MD) Technologist
Analysis time 15 – 45 minutes 5 minutes
Reader Radiologist – 15 minutes Cardiologist – 1 minute
Workflow
1st appt with cardiologist
2nd appt for MRI (months)
3rd appt with cardiologist
Scan and analysis during
1st appointment with
cardiologist
Capital Cost $2 – 4 million $50,000
TSXV:VPT
5
6. Ventripoint VMS+ 3.0 System
Processes all standard 2D echocardiograms to generate MRI equivalent 3D cardiac metrics
Interfaces with all
standard echocardiogram
2D cardiac ultrasound
machines (GE, Siemens,
Philips, Toshiba)
provides Cardiologists
confidence in their diagnosis
10 year $30M development
of 3rd generation AI
software has now elevated
2D echocardiogram to MRI
level accuracy
The Solution
11. Market Opportunity
Ventripoint has identified key market segments to drive sales
Congenital Heart Defects (CHD)
Standard-of-care guidelines require patient follow-up every
three months for life
Pulmonary Hypertension (PAH)
Significant patient population
Cardiotoxic Effects of Chemotherapy
20 – 30% of oncology patients experience heart damage
COVID-19 Patients
Virus causes heart damage in a high percentage of patients
Companion Animals
10% of 100M dogs in USA have heart issues
* In each case, Ventripoint can provide clinically
important data faster and at less expense than MRI
TSXV:VPT
11
12. Clinical Need
HEART DISEASE IS THE LEADING CAUSE OF
DEATH FOR BOTH MEN AND WOMEN
WORLDWIDE
CARDIAC MEASUREMENTS ARE
CRITICAL TO ASSESS HEART DISEASE
1.4 BILLION SPENT ON NEW
ECHOCARDIOGRAM MACHINES EACH YEAR
200 BILLION SPENT ON CARDIOVASCULAR
DISEASE IN US ANNUALLY
13. Key Recent Placements
MD Anderson Cancer Center
Houston, TX – October 2020
Erasmus-Sophia University Medical Center
The Netherlands - September 2020
Peter Munk
Cardiac Centre-
UHN
Toronto,
Canada -
November
2020
TSXV:VPT
13
King’s College Hospital London,
UK - Dec 2020
14. Market Entry w/KOL’s
Key Opinion Leaders (KOL) per market segment to evaluate
system and present/publish at major medical conferences
Host Regional Ventripoint-moderated webinars featuring
KOLs with VMS+3.0 experience. Two webinars planned in
1Q21 – one each for North America and Europe
Publish multiyear experience of major heart centre using
VMS to monitor CHD in children
Association-sponsored webinars
American Adult Congenital Heart Disease Association
Will increase awareness as marketed to physician
databases
15. Installed Ultrasound Base VMS+3.0
Opportunity
Application USA Canada Europe Total
Oncology 10,000 1,000 15,000 26,000
Pulmonary
Hypertension
2,000 200 3,000 5,500
Congenital 4,000 400 6,000 11,000
Total 16,000 1,600 24,000 41,600
• VMS+3.0 can be integrated with any common ultrasound system
• USD$50,000 per placement imputes a $2B+ market opportunity
16. Revenue Model
List price of USD $50,000 per unit
$5K annual licence fee generates recurring revenue
Patient patch consumable per procedure
Sales focused on 41,600 unit installed base of ultrasound
systems
Pay-per-use model to reduce barriers to system acquisition
lease for $15K/year (first 200 cases free)
$50/case thereafter
US customers able to access existing reimbursement code (76377):
$98 - $200 per case
Rapid breakeven (75-150 cases)
TSXV:VPT 16
17. Early Sales Traction
11 sites completed and 11 sites in process
Hospital committed placements include:
Can – 5 sites completed/2 additional sites in process
US – 1 site completed/4 additional sites in process
UK – 1 site completed and 3 sites in process
Europe – 1 site completed/2 sites in process
China – 3 sites completed
VPT anticipates that multiple units will be purchased regularly
by each hospital that uses the VMS+3.0.
TSXV:VPT 17
18. Companion Animals
• Initiated collaboration with Veterinary School at
North Carolina Sate University to validate use of
VMS+3.0 on dogs.
• Initial studies show existing databases work
correctly and reconstructions accurate
• 37% of households in USA have adopted a pet in
last 12 months (Bank of America Study)
• Over 100M companion dogs in USA and 10% have
heart disease
• 30,000 veterinary practices in USA
19. Exit Opportunities
Acquisition by multinational ultrasound
company such as Philips, Siemens, GE,
Samsung
Ventripoint will be of interest when it
reaches 80 – 100 installed sites
Recent acquisition of TomTech by Philips for
more than USD$100M
Acquisition by service provider such as
McKesson, Circle or PIA
* Growing sales, recurring revenues and 80%
margins are attractive
20. • Mr. Hirson is a seasoned executive with over 20 years of experience in commercializing medical devices and
managing product development, manufacturing operations, regulatory and quality assurance
• Previously as Vice President Engineering at Sonosite and was part of the acquisition by FUJIFILM , Mr. Hirson led a
development team to commercialize novel ultrasound technology from prototype to market success in
cardiovascular, cancer and other areas of pre-clinical research that also resulted in ground-breaking clinical
applications
Desmond Hirson, Chief Technology Officer
• Dr. Adams is known as a scientist, innovator, entrepreneur and venture financier. Using his medical and
engineering knowledge he has spent 40 years developing and commercializing medical discoveries related to the
heart and blood vessels. The products which he has commercialized have been implanted or used to support life in
300 million people in the last 35 years. Dr Adams was named a Technology Pioneer by the World Economic Forum,
attended the Davos meeting and featured in Time magazine worldwide.
George Adams PhD, CEO
Experienced Leadership Team
Alvira Macanovic, PhD, Senior Director, Operations, Regulatory Affairs & Quality Assurance
• Dr. Macanovic has over 10 years of experience in pharmaceutical and medical device related industries, where she
has worked with researchers, start-ups, SMEs, and multi-national companies to commercialize technologies in
multiple therapeutic areas
• At a prior start-up focused on medical imaging, Dr. Macanovic oversaw all aspects of the regulatory affairs/quality
operations for the successful launch of the company’s products in Canada, the United States, and China
• Mr. McPhedran brings over 30 years of capital equipment sales experience in the medical industry including both
medical imaging and laboratory diagnostics
• As Sales Director for Siemens Healthcare, Mr. McPhedran lead a dynamic sales team responsible for the sale of the
full portfolio of diagnostic imaging equipment and thin client network solutions for advanced post processing of
imaging data in Western Canada with an annual target of over 35M per year
Dave McPhedran, Global Sales Director
21. Key Investment Considerations
$2B+ market opportunity
Substantially de-risked – product is developed,
regulatory approvals in hand and sales successfully
under way
Recent acquisitions suggest valuations of greater
than USD$100M very feasible
Proven team has accomplished similar plans
multiple times in the past
Current valuation of ~USD$30M enables excellent
return
22. Thank You
For further information contact:
Dr. George Adams – CEO
gadams@ventripoint.com
Ventripoint Diagnostics Ltd.
2 Sheppard Avenue East, Suite 605
Toronto Ontario M2N 5Y7 Canada
(519) 803-6937
Investor Relations:
Clay Chase @ Torrey Hills Capital
(858) 456-7300
cc@sdthc.com
Website: www.ventripoint.com
OTC: VPTDF & TSX-V: VPT
Editor's Notes
Extra money spent on customization of the EMR systems
Patients suffer because data is difficult to extract form these systems.
Extra money spent on customization of the EMR systems
Patients suffer because data is difficult to extract form these systems.